Products
Latest News
FAQ
Log in
|
Search
Search
Filters
Clear All
Study Phase
Early Phase 1
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
Phase 4
Not Applicable
Recruitment Status
Recruiting
Not yet recruiting
Active, not recruiting
Completed
Suspended
Terminated
Withdrawn
Study Type
Interventional
Observational
Expanded Access
Others
Eligibility Sex
All
Female
Male
Healthy Volunteers
All
Include
Exclude
Found
1
clinical trials
|
View Analysis
Sort by:
Newest First
Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)
Phase 2
Terminated
Conditions
Leukemia, Myelogenous, Acute
Interventions
Biological: Natural Killer Cells
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Denileukin diftitox
Procedure: Donor lymphapheresis
Drug: IL-2
Subscribe
First Posted Date
2010-04-20
Last Posted Date
2017-12-28
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
15
Registration Number
NCT01106950
Locations
🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Subscribe
Prev
1
Next
© Copyright 2025. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy